Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

HealthWell Foundation introduces new lupus fund

The HealthWell Foundation, a nonprofit organization providing financial assistance to insured patients facing a variety of chronic and life-altering illnesses, announces the launch of a new fund supporting treatment for Systemic Lupus Erythematosus (SLE), the most common form of lupus.

22 Sep 2011

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

21 Sep 2011

African-American men living in low sunlight areas more likely to have Vitamin D deficiency

African-American men living in areas with low sunlight are up to 3 - times more likely to have Vitamin D deficiency than Caucasian men and should take high levels of Vitamin D supplements, according to a new study from Northwestern University Feinberg School of Medicine.

21 Sep 2011

Akeso Medical Imaging closes first financing round to develop imaging device for rheumatoid arthritis disease activity monitoring and control

Akeso Medical Imaging BV, a spin-off from Philips Research, announces today the closure of its first financing round led by Thuja Capital Healthcare Seed Fund with additional financing from the Brabant Spin-Off Fund and Point-One Innovation Fund.

20 Sep 2011

ACR launches Simple Tasks campaign to raise awareness on rheumatic diseases

The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.

20 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

New report finds decline in clinical trial recruitment for autoimmune disorders

The number of patients recruited to clinical trials for autoimmune disorders has waned in the last ten years, according to a new report available on companiesandmarkets.com.

19 Sep 2011

Novel therapies remove the brakes cancer puts on the immune system

Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system, Georgia Health Sciences University researchers report.

17 Sep 2011

New insight into how nervous system regulates immunity

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science.

17 Sep 2011

Positive results from PROLOR Biotech's Factor VIIa-CTP preclinical study on hemophilia

PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.

15 Sep 2011

Roundup: N.J. Governor opts not to cut Medicaid rolls; Seattle council mandates sick leave

Thousands of New Jersey's working poor will keep their health insurance under a new administration proposal to restructure Medicaid, abandoning a controversial plan that would have drastically reduced the number of eligible recipients.

14 Sep 2011

Lexicon's LX4211 clinical data presented at EASD annual meeting

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

14 Sep 2011

Human gliomas release excess levels of glutamate and trigger seizures

Glioma, one of the most deadly and common types of brain tumor, is often associated with seizures, but the origins of these seizures and effective treatments for them have been elusive. Now a team funded by the National Institutes of Health has found that human gliomas implanted in mice release excess levels of the brain chemical glutamate, overstimulating neurons near the tumor and triggering seizures.

12 Sep 2011

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Nektar Therapeutics announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.

12 Sep 2011

Researchers identify bouncer protein that plays a vital role in RA prevention

Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

8 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

An international team of researchers has found a group of mutations involved in T-cell acute lymphoblastic leukemia (T-ALL), and showed that a group of certain drugs, already in clinical use to treat other diseases, can eliminate the cells carrying these mutations.

5 Sep 2011

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

HealthWell Foundation introduces new lupus fund

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

African-American men living in low sunlight areas more likely to have Vitamin D deficiency

Akeso Medical Imaging closes first financing round to develop imaging device for rheumatoid arthritis disease activity monitoring and control

ACR launches Simple Tasks campaign to raise awareness on rheumatic diseases

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

New report finds decline in clinical trial recruitment for autoimmune disorders

Novel therapies remove the brakes cancer puts on the immune system

New insight into how nervous system regulates immunity

Positive results from PROLOR Biotech's Factor VIIa-CTP preclinical study on hemophilia

Roundup: N.J. Governor opts not to cut Medicaid rolls; Seattle council mandates sick leave

Lexicon's LX4211 clinical data presented at EASD annual meeting

Human gliomas release excess levels of glutamate and trigger seizures

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Researchers identify bouncer protein that plays a vital role in RA prevention

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

FDA panel on post-approval studies of silicone breast implants

SQI Diagnostics third quarter net loss increases to $2,691,000

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in